查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855678

手術部位感染控制市場按產品類型、最終用戶、應用和手術類型分類 - 全球預測 2025-2032

Surgical Site Infection Control Market by Product Type, End User, Application, Surgery Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，手術部位感染控制市場規模將達到 93.3 億美元，複合年成長率為 6.52%。

關鍵市場統計數據
基準年 2024 56.2億美元
預計年份：2025年 59.9億美元
預測年份 2032 93.3億美元
複合年成長率 (%) 6.52%

闡明手術部位感染控制在臨床路徑、採購優先事項和多學科醫療服務體系中的關鍵作用

手術部位感染仍然是手術全期護理中最嚴重的併發症之一，它會影響臨床療效、病人安全和醫療機構的成本結構。本導言整合了塑造當今感染預防策略的臨床原理、營運壓力和不斷發展的技術方法。它將感染控制定位為一項跨職能的優先事項，而不僅僅是合規性活動，它整合了手術技術、設備選擇、手術全期方案和供應鏈彈性，以形成連貫的護理路徑，旨在減少不利事件並改善康復進程。

開篇分析重點闡述了外科醫生、護理團隊、感染控制專家和採購人員之間的跨學科協作對於實施循證干預措施至關重要。它概述了材料科學、抗菌技術和傷口管理器械的最新進展如何應用，以及皮膚準備和術中沖洗的標準化流程。此外，它還透過強調臨床療效、易於融入手術流程以及需要強力的上市後監測來檢驗長期獲益和安全性等因素之間的相互作用，為深入探討市場動態奠定了基礎。

本報告圍繞著醫院領導和門診醫護人員的實用決策標準組裝，強調決策必須兼顧臨床療效、營運效率和總醫療成本。該報告還強調了數據驅動主導的重要性，包括真實世界證據和註冊數據，以指導新感染控制措施的採購和臨床應用。本引言透過明確目標為後續章節奠定了基礎：降低感染髮生率、縮短住院時間、改善患者預後，同時保持營運效率和合規性。

技術進步、監管預期和醫療服務模式的轉變如何重新定義手術部位感染控制的預防策略和採購重點

由於技術創新、監管審查以及醫療服務提供者期望的改變，手術部位感染預防領域正在發生顯著變化。新型材料和器械設計，例如抗菌縫合線和先進的傷口敷料，與數位監測工具相輔相成，能夠更早發現傷口併發症並進行更積極的術後管理。同時，臨床醫師正在完善圍手術全期流程，將術前皮膚準備方案與術中傷口沖洗和術後傷口監測相結合，從而建立無縫銜接的預防策略。

醫療保健系統也在調整採購和供應鏈模式，以同時適應一次性醫療器械和傳統醫療器械，並更加關注生命週期成本、消毒流程和環境影響。隨著報銷框架的演變，更加重視療效和價值導向醫療，醫院和門診中心獎勵採取能夠顯著降低再入院率並提高出院後護理品質的干涉措施。同時，監管機構提高了對上市後證據收集的要求，鼓勵製造商投資於能夠證明產品在真實世界中有效性和安全性的強力的臨床項目。

另一個重要變化是外科手術服務的去中心化，越來越多的手術轉移到門診手術中心和門診診所進行。這一趨勢要求感染控制產品能夠適用於不同的醫療環境，並適應不同的消毒和人員配備模式。此外，隨著醫療機構尋求降低全球供應中斷帶來的風險，供應鏈多元化和本地籌資策略正日益受到重視。同時，一次性系統和模組化設備的創新有望簡化庫存管理並降低交叉感染的風險。

評估2025年美國累積關稅措施如何再形成感染控制產品的供應鏈韌性、採購決策和採購動態。

美國將於2025年實施累積關稅，這將為手術部位感染控制產品的供應鏈和籌資策略帶來新的複雜性。進口關稅將影響成本結構，尤其是那些零件和製造地位於美國境外的設備和耗材。直接影響將體現在到岸成本的增加上，迫使採購團隊重新評估供應商合約、重新談判條款，並探索其他採購方案，以維持利潤率和業務永續營運。

除了採購成本之外，關稅還可能透過加速對區域製造、近岸外包或調整合約轉移定價的投資來改變供應商的行為。製造商可能會透過將抗菌塗層、敷料基材和一次性系統組件等零件的生產本地化來應對，以減輕關稅的影響。這些變化將影響交貨前置作業時間、產品供應和新產品上市的靈活性。因此，醫療機構需要調整其庫存計劃和臨床實施時間表，以應對潛在的供應商轉型和產能推出期。

關稅主導的動態也將影響醫療服務提供者和製造商之間的價格談判。大型醫院和門診中心可能會利用其規模優勢來獲得優惠價格和長期契約，而小型診所和獨立中心則可能對價格更為敏感。此外，關稅的影響在不同產品類型中並不相同，原料進口密集度高的產品和特殊組件更容易受到成本轉嫁的影響。因應策略包括供應商多元化、投資需求預測以及參與供應商合作，以在維持臨床標準的同時穩定供應。

主導深度細分的洞察，將產品類型、最終用戶情況、應用領域和外科專科與臨床應用路徑和採購方案進行配對。

深入了解市場細分對於將臨床需求與產品功能和籌資策略相匹配至關重要。從產品類型角度來看，抗菌縫合線、負壓傷口護理裝置、外科敷料和局部消毒劑之間的差異更加清晰，從而揭示了創新和應用的重點領域。抗菌縫合線（包括銀塗層縫合線和三氯生塗層縫合線）的評估指標包括：減少縫合線微生物定植的能力、與各種組織類型的相容性以及在外科手術中的應用。傷口護理裝置（包括一次性使用系統和傳統系統）的評估指標包括：在住院和門診病人環境中的易用性、一次性使用注意事項以及減少換藥頻率和促進傷口縫合的潛力。

外科敷料分為藻酸鹽敷料、泡棉敷料和親水膠體敷料，它們在滲出液管理、貼合性和黏附性等方面各有不同，因此適用於不同類型的傷口和不同的解剖部位。局部消毒劑包括酒精類、洛赫西定和優碘類製劑，必須根據頻譜、皮膚耐受性和與術前皮膚準備流程的兼容性進行評估。這些產品層面的差異指南臨床醫師選擇兼顧抗菌活性、組織安全性和手術效率的介入措施。

終端用戶細分透過揭示營運環境，進一步細化了策略考量。門診手術中心（包括獨立中心和醫院附屬中心）通常優先考慮快速週轉、一次性使用便利性和庫存合理化，而診所（分為門診部和專科診所）可能更重視產品的多功能性和成本控制。醫院（分為私立醫院和公立醫院）通常需要擴充性的解決方案，這些方案能夠與現有的無菌處理和多學科通訊協定相整合，並且通常需要詳細的臨床結果和成本影響方面的證據，以支持全系統範圍內的推廣應用。

基於應用的分割結果顯示，介入措施能帶來最顯著的臨床效益。術中傷口沖洗（包括生理食鹽水沖洗和生理食鹽水沖洗等）在減少手術污染方面發揮特殊作用。術後傷口管理（包括換藥和清創）的重點在於維持無菌環境，並在術後數天內促進組織癒合。術前皮膚準備（分為洛赫西定定消毒和優碘消毒）對於減少切口前皮膚微生物群污染至關重要。每種應用途徑都有其獨特的效能標準、供應鏈考量和人員訓練要求。

最後，按手術類型細分，可以揭示影響產品選擇和方案設計的臨床優先事項。心血管手術，包括冠狀動脈繞道手術和瓣膜置換術，對無菌操作和高風險因素有嚴格的要求。一般外科手術，包括腹部和胃腸道手術，傷口狀況各異，需要採用適應性敷料策略。婦產科手術，包括剖腹產和子宮切除術，強調母體安全和術後快速復健；而整形外科，包括關節重建和脊椎手術，則在植入物較多的環境中優先考慮感染預防。將這些細分層級結合起來，可以建立一個綜合框架，以支援針對特定手術場景的有針對性的臨床評估、植入談判和推廣藍圖。

主要全球區域醫療基礎設施、採購機制和監管方面的差異如何影響感染預防措施的採用和供應鏈策略

區域動態對預防手術部位感染的供應鏈策略、產品應用和臨床實務模式有顯著影響。在美洲，醫療保健系統涵蓋大型綜合醫療服務網路、社區醫院和獨立手術中心，每個系統都有不同的採購優勢和營運重點。該地區對能夠降低再入院率並與基於價值的支付指標相整合的解決方案表現出濃厚的興趣，同時還需兼顧影響產品應用和臨床方案的獨特監管路徑和報銷細則。

歐洲、中東和非洲是一個異質性區域，監管環境、報銷機制和醫療基礎設施成熟度差異巨大。西方體系通常強調實證實施和完善的上市後監測，而該區域的新興市場則可能優先考慮成本效益高、易於實施的干涉措施和穩健的供應鏈。公共採購機制和集中採購塑造了該區域許多國家感染控制產品的競爭動態。

亞太地區涵蓋了從先進的三級醫療中心到快速擴張的門診網路等多種醫療服務環境。該地區的特點是大力投資醫院基礎設施建設，並日益重視手術品質指標。為了滿足需求、應對關稅和貿易方面的考慮，以及支援產品快速註冊，該地區的供應鏈策略越來越傾向於在地化生產和區域合作。在所有地區，臨床證據要求、採購模式和當地監管預期之間的相互作用將決定新興感染預防技術​​的應用速度和範圍。

醫療器材和創傷護理創新者的競爭格局和策略定位，重點在於證據生成、夥伴關係和模組化解決方案設計

對競爭格局的分析表明，手術部位感染預防領域涵蓋了許多參與者，從成熟的醫療設備製造商到創傷護理專家，再到新興創新者。擁有廣泛產品組合的公司通常憑藉其整合解決方案、成熟的臨床證據以及覆蓋醫院和門診客戶的廣泛分銷網路展開競爭。相反，專注於特定領域的公司則傾向於透過專注的技術實現差異化，例如新型抗菌塗層、一次性負壓系統或針對特定臨床需求的高級敷料。

該領域的策略措施包括：強調臨床夥伴關係、投資隨機對照試驗和基於註冊研究的證據，以及與醫療系統合作試點打包式診療路徑。經營模式正轉向價值驗證，製造商提供令人信服的真實世界數據來支持採購談判，例如減少併發症、縮短住院時間和改善患者報告的療效。此外，醫療器材製造商與臨床解決方案供應商合作，打造打包式產品，簡化醫院和門診中心的決策流程，這種做法也越來越普遍。

從產品開發的角度來看，投資於模組化、可互操作系統和以使用者為中心的設計的公司，在重視工作流程效率的環境中，更有可能獲得快速的市場認可。此外，在追求規模化、分銷和互補技術整合的驅動下，某些產品類型也呈現出整合的趨勢。最終，競爭優勢越來越取決於建立強大的臨床證據基礎、確保供應連續性以及使商業模式與醫療機構的報銷獎勵和營運流程相契合的能力。

產業領導者採取切實可行的策略行動，以加強證據產生、供應鏈韌性和感染預防產品的臨床應用。

產業領導者可以採取多種切實可行的策略來提升臨床療效，並確保在手術部位感染控制方面獲得永續的商業性優勢。首先，他們可以透過優先投資高品質的真實世界臨床證據，加快醫院和門診中心的推廣應用。這包括設計能夠反映不同患者群體和手術類型的試驗和註冊研究，同時收集對臨床醫生和支付者都至關重要的療效指標。

其次，將產品開發與工作流程最佳化和臨床醫生培訓相結合，可以提高產品成功推廣的可能性。能夠最大限度地減少對既定手術流程干擾、減輕換藥和設備安裝過程中醫護人員負擔，並提供清晰訓練路徑的設備和耗材，更容易獲得更高的推廣率。多元化製造地、尋求區域夥伴關係以及製定緊急庫存策略，可以降低關稅和中斷風險。與主要客戶和供應商建立合作模式，可以提高可預測性，並共用承擔臨床結果的課責。

第四，商業策略必須日益與價值驗證結合。建立試驗計畫、基於結果的合約或捆綁式報價試點項目，可以為更廣泛的採購承諾鋪平道路。最後，領導者必須重視跨相關人員的參與，確保外科、護理、感染控制和供應鏈團隊共同負責感染預防舉措，以最佳化方案執行並全面評估其影響。採取這些集體行動將使各機構能夠在降低感染風險的同時，保持財務和營運與不斷變化的醫療保健優先事項的一致性。

採用嚴謹的混合方法研究途徑，結合一手臨床見解、二手文獻綜合和產品比較分析，以得出策略性結論。

本分析的調查方法結合了第一手資料和第二手資料，以確保依證的平衡性。第一手資料包括對臨床負責人、採購專業人員和醫療器材創新者的結構化訪談，並輔以諮詢顧問，探討實際應用中的挑戰和證據需求。第二手資料包括同行評審的臨床文獻、監管指導文件和公開的技術規範，以支援產品性能聲明，並識別應用趨勢和護理標準。

分析方法包括產品比較分析，以評估縫線、傷口護理系統、敷料和消毒劑的功能差異；以及情境分析，以評估供應鍊和關稅對採購決策的潛在影響。採用三角測量法來協調相關人員的觀點差異，確保建議既反映臨床優先事項，也符合實際操作情況。調查方法和資料來源強調資料收集的透明度，優先考慮臨床相關性，並透過納入來自不同醫療機構的多元觀點來盡量減少偏見。

為持續降低手術部位感染和手術風險，臨床醫師和採購團隊需優先考慮以下綜合事項。

總之，有效的手術部位感染控制需要多管齊下的策略，包括產品選擇、方案設計和供應鏈規劃。臨床醫師和採購團隊必須通力合作，將臨床證據與操作可行性結合，確保所選干預措施既能造福患者，又能為機構帶來價值。新技術和完善的圍手術全期方案為降低感染風險提供了有希望的途徑，但其成功應用取決於可靠的證據、工作流程的兼容性以及穩健的籌資策略。

隨著醫療領域面臨關稅調整、監管預期變化以及醫療服務模式演變等挑戰，積極投資於臨床檢驗、供應商合作以及以結果為導向的商業性模式的機構，將更有利於持續提升手術品質。本分析旨在為決策者提供所需的洞見，幫助他們確定各項措施的優先順序、評估供應商提案，並實施能夠全面提升病患安全和營運績效的通訊協定。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 引入抗菌縫線和屏障以降低術後感染率
  • 將UV-C紫外線消毒機器人整合到自動化手術室表面消毒系統中
  • 採用即時遠端傷口監測技術早期發現感染
  • 改用一次性無菌手術器械，以最大程度地降低交叉感染風險。
  • 開發可促進術後創傷治療的生物可吸收抗菌敷料
  • 監管獎勵鼓勵醫院投資先進的感染監測系統
  • 擴大遠端醫療驅動的術前皮膚準備培訓，惠及偏遠地區的主導

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按產品類型分類的手術部位感染控制市場

  • 抗菌縫合線
    • 鍍銀縫合線
    • 三氯生塗層縫合線
  • 傷口護理裝置
    • 免洗系統
    • 傳統系統
  • 外科敷料
    • 海藻酸鹽敷料
    • 泡棉敷料
    • 親水膠體敷料
  • 局部消毒劑
    • 酒精類
    • 洛赫西定定
    • 優碘基

第9章 依最終用戶分類的手術部位感染控制市場

  • 門診手術中心
    • 獨立中心
    • 醫院附設中心
  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院

第10章：按應用分類的手術部位感染控制市場

  • 術中傷口沖洗
    • 抗生素灌注
    • 生理食鹽水食鹽水灌注
  • 術後傷口管理
    • 換裝
    • 傷口撕脫
  • 術前皮膚準備
    • 洛赫西定定製劑
    • 優碘製劑

第11章 依手術類型分類的手術部位感染控制市場

  • 心血管外科
    • 冠狀動脈繞道手術手術
    • 置換術
  • 一般外科
    • 腹部手術
    • 胃腸道手術
  • 婦科手術
    • 剖腹產
    • 子宮切除術
  • 整形外科
    • 關節重建
    • 脊椎手術

第12章 各地區手術部位感染控制市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按組別分類的手術部位感染控制市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國手術部位感染控制市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • 3M Company
    • Johnson & Johnson
    • Becton, Dickinson and Company
    • Cardinal Health, Inc.
    • STERIS plc
    • Ecolab Inc.
    • B. Braun Melsungen AG
    • Getinge AB
    • Molnlycke Health Care AB
    • Smith & Nephew plc
Product Code: MRR-62667ADF9A51

The Surgical Site Infection Control Market is projected to grow by USD 9.33 billion at a CAGR of 6.52% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.62 billion
Estimated Year [2025] USD 5.99 billion
Forecast Year [2032] USD 9.33 billion
CAGR (%) 6.52%

Framing the critical role of surgical site infection control across clinical pathways, procurement priorities, and multidisciplinary care delivery systems

Surgical site infections remain one of the most consequential complications in perioperative care, with implications that extend across clinical outcomes, patient safety, and institutional cost structures. This introduction synthesizes the clinical rationale, operational pressures, and evolving technological approaches that shape infection prevention strategies today. It positions infection control not merely as a compliance activity but as a cross-functional priority that integrates surgical technique, device selection, perioperative protocols, and supply chain resilience into a coherent care pathway aimed at reducing adverse events and improving recovery trajectories.

The opening analysis emphasizes how multidisciplinary coordination among surgeons, nursing teams, infection prevention specialists, and procurement professionals is critical to implementing evidence-based interventions. It outlines how advances in materials science, antimicrobial technologies, and wound management devices are being adopted alongside standardized protocols for skin preparation and intraoperative irrigation. The narrative sets the stage for deeper exploration of market dynamics by highlighting the intersection of clinical efficacy, ease of integration into surgical workflows, and the need for robust post-market surveillance to validate long-term benefits and safety profiles.

Moving forward, the report frames the conversation around practical decision criteria for hospital leaders and ambulatory providers, stressing that choices must balance clinical performance, operational compatibility, and total cost of care. It also underscores the importance of data-driven evaluation, including real-world evidence and registry data, to guide procurement and clinical adoption of new infection control modalities. This introduction establishes the foundation for subsequent sections by clarifying objectives: reduce infection incidence, shorten length of stay, and improve patient outcomes while maintaining operational efficiency and regulatory compliance.

How technological advances, regulatory expectations, and care delivery shifts are redefining prevention strategies and procurement priorities in surgical site infection control

The landscape of surgical site infection control is undergoing transformative shifts driven by technological innovation, regulatory scrutiny, and changing provider expectations. New materials and device designs, such as antimicrobial-embedded sutures and advanced wound dressings, are complemented by digital monitoring tools that enable earlier detection of wound complications and more proactive postoperative management. Concurrently, clinicians are refining perioperative bundles that integrate preoperative skin preparation protocols with intraoperative wound irrigation practices and postoperative wound surveillance to create seamless prevention strategies.

Healthcare systems are also adapting procurement and supply chain models to accommodate both single-use and traditional devices, with increasing emphasis on lifecycle cost, sterilization workflows, and environmental impact. As reimbursement frameworks evolve to prioritize outcomes and value-based care, hospitals and ambulatory centers are incentivized to adopt interventions that demonstrably reduce readmissions and extend care quality beyond discharge. In parallel, regulatory bodies are heightening expectations for post-market evidence collection, driving manufacturers to invest in robust clinical programs that substantiate real-world effectiveness and safety.

Another important shift is the decentralization of surgical care, with more procedures migrating to ambulatory surgical centers and outpatient clinics. This trend necessitates infection control products that are versatile across different care settings and compatible with varying sterilization and staffing models. Finally, supply chain diversification and regional sourcing strategies are gaining traction as providers seek to mitigate risks associated with global disruptions, while innovation in single-use systems and modular devices promises to simplify inventory management and reduce cross-contamination risks.

Assessing how cumulative United States tariff measures in 2025 are reshaping supply chain resilience, sourcing decisions, and procurement dynamics for infection control products

The introduction of cumulative tariff measures in the United States in 2025 has introduced a new dimension of complexity for supply chains and procurement strategies across surgical site infection control products. Import tariffs influence the cost structure of devices and consumables, particularly those with components or manufacturing footprints outside domestic markets. The immediate impact is felt through increased landed costs, prompting procurement teams to reassess supplier contracts, renegotiate terms, and explore alternative sourcing options to maintain margin and operational continuity.

Beyond acquisition costs, tariffs can alter supplier behavior by accelerating investments in regional manufacturing, nearshoring, or contractual transfer pricing adjustments. Manufacturers may respond by localizing production for components such as antimicrobial coatings, dressing substrates, and single-use system assemblies to avoid tariff exposure. These shifts have implications for lead times, product availability, and the agility of new product launches. Providers must therefore recalibrate inventory planning and clinical adoption timelines to reflect potential supplier transitions and capacity ramp-up periods.

Tariff-driven dynamics also affect pricing negotiations between providers and manufacturers. Hospitals and ambulatory centers with larger purchasing volumes may leverage scale to secure concessional pricing or long-term agreements, whereas smaller clinics and freestanding centers could face greater price sensitivity. In addition, tariff impacts are not uniform across product categories; items with high raw material import intensity or specialized components are more susceptible to cost pass-through. Strategic responses include diversifying supplier bases, investing in demand forecasting, and engaging in collaborative supplier development to stabilize supply while preserving clinical standards.

Deep segmentation-driven insights that map product types, end user contexts, applications, and surgical specialties to clinical adoption pathways and procurement choices

A granular understanding of segmentation is essential to align clinical needs with product capabilities and procurement strategies. When viewed through the lens of product type, distinctions between Antimicrobial Sutures, Negative Pressure Wound Therapy Devices, Surgical Dressings, and Topical Antiseptics clarify where innovation and adoption are concentrated. Antimicrobial Sutures, including Silver-Coated Sutures and Triclosan-Coated Sutures, are evaluated for their role in reducing microbial colonization at the suture line, compatibility with various tissue types, and their integration into surgical technique. Negative Pressure Wound Therapy Devices, which encompass Single-Use Systems and Traditional Systems, are assessed for ease of deployment in both inpatient and outpatient settings, disposability considerations, and the potential to reduce dressing change frequency and promote wound closure dynamics.

Surgical Dressings, categorized into Alginate Dressings, Foam Dressings, and Hydrocolloid Dressings, present differentiated performance characteristics such as exudate management, conformability, and adhesion properties that influence their suitability across wound types and anatomical locations. Topical Antiseptics, spanning Alcohol-Based, Chlorhexidine-Based, and Povidone-Iodine-Based formulations, require evaluation based on spectrum of antimicrobial activity, skin tolerance, and procedural workflow compatibility for preoperative skin preparation. These product-level distinctions guide clinicians in selecting interventions that balance antimicrobial potency with tissue safety and procedural efficiency.

End-user segmentation further refines strategic considerations by highlighting operational contexts. Ambulatory Surgical Centers, which include Freestanding Centers and Hospital Affiliated Centers, often prioritize rapid turnaround, single-use convenience, and streamlined inventory, whereas Clinics, differentiated into Outpatient Clinics and Specialty Clinics, may emphasize product versatility and cost containment. Hospitals, split across Private Hospitals and Public Hospitals, typically demand scalable solutions that integrate with established sterile processing and multidisciplinary protocols, and they often require detailed evidence of clinical outcomes and cost implications to support system-wide adoption.

Application-based segmentation surfaces where interventions deliver the most measurable clinical benefit. Intraoperative Wound Irrigation, with subsets such as Antibiotic Irrigation and Saline Irrigation, plays a specific role in contaminant reduction at the time of surgery. Postoperative Wound Management, including Dressing Changes and Wound Debridement, focuses on maintaining a sterile environment and promoting tissue healing in the days following surgery. Preoperative Skin Preparation, differentiated into Chlorhexidine Preparation and Povidone-Iodine Preparation, is foundational for reducing skin flora contamination prior to incision. Each application pathway demands unique performance criteria, supply chain considerations, and staff training implications.

Finally, segmentation by surgery type reveals clinical priorities that influence product selection and protocol design. Cardiovascular Surgery, covering Coronary Artery Bypass and Valve Replacement, imposes stringent sterility and high-risk considerations. General Surgery, with Abdominal Procedures and Gastrointestinal Procedures, presents diverse wound profiles requiring adaptable dressing strategies. Obstetrics and Gynecology Surgery, including C Section and Hysterectomy, places emphasis on maternal safety and rapid postoperative recovery, while Orthopedic Surgery, encompassing Joint Replacement and Spinal Surgery, prioritizes infection prevention in implant-rich environments. Together, these segmentation layers create a composite framework that supports targeted clinical evaluations, procurement negotiations, and adoption roadmaps tailored to specific procedural contexts.

How regional healthcare infrastructure, procurement mechanisms, and regulatory diversity across major global regions shape adoption and supply chain strategies for infection control

Regional dynamics significantly influence supply chain strategies, product adoption, and clinical practice patterns across surgical site infection prevention. In the Americas, healthcare systems vary from large integrated delivery networks to community hospitals and freestanding surgical centers, each with differing procurement leverage and operational priorities. This region shows active interest in solutions that reduce readmissions and integrate with value-based payment metrics, while also balancing localized regulatory pathways and reimbursement nuances that affect uptake and clinical protocols.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks, reimbursement environments, and healthcare infrastructure maturity diverge widely. Western European systems often emphasize evidence-based adoption with robust post-market surveillance, whereas emerging markets within the region may prioritize cost-effective, easy-to-deploy interventions and supply chain robustness. In many countries across this region, public procurement mechanisms and centralized purchasing can shape the competitive dynamics for infection control products.

Asia-Pacific encompasses a broad spectrum of healthcare delivery settings, from advanced tertiary centers to rapidly expanding ambulatory networks. The region is characterized by significant investment in hospital infrastructure and a growing focus on surgical quality metrics. Supply chain strategies here increasingly favor local manufacturing and regional partnerships to meet demand, address tariff and trade considerations, and support faster product registration. Across all regions, the interplay between clinical evidence requirements, procurement models, and local regulatory expectations will determine the speed and extent of adoption for new infection prevention technologies.

Competitive landscape and strategic positioning of device and wound care innovators emphasizing evidence generation, partnerships, and modular solution design

A review of the competitive ecosystem highlights the diversity of players engaging in the surgical site infection control arena, from established medical device manufacturers to specialized wound care firms and emergent innovators. Companies with broad portfolios typically compete on the basis of integrated solutions, established clinical evidence, and extensive distribution networks that support hospital and ambulatory customers. Conversely, niche players often differentiate through focused technologies such as novel antimicrobial coatings, single-use negative pressure systems, or advanced dressing materials that target specific clinical gaps.

Strategic behaviors observed in the sector include increased emphasis on clinical partnerships, investment in randomized trials and registry-based evidence, and collaborations with health systems to pilot bundled care pathways. Business models are shifting toward value demonstration, where manufacturers present compelling real-world data on reduced complications, shorter lengths of stay, and improved patient-reported outcomes to support procurement discussions. Additionally, partnerships between device makers and clinical solution providers are becoming more common to create bundled offerings that simplify decision-making for hospitals and ambulatory centers.

From a product development perspective, companies investing in modular, interoperable systems and in user-centered design tend to gain quicker adoption in settings that prioritize workflow efficiency. The landscape also shows consolidation trends in specific product categories, driven by the quest for scale, distribution reach, and complementary technology integration. Ultimately, competitive advantage is increasingly defined by the ability to produce robust clinical evidence, ensure supply continuity, and align commercial models with institutional reimbursement incentives and operational workflows.

Practical strategic actions for industry leaders to strengthen evidence generation, supply chain resilience, and clinical adoption for infection prevention products

Industry leaders can adopt several actionable strategies to strengthen clinical outcomes and secure sustainable commercial advantage in surgical site infection control. First, prioritizing investments in high-quality clinical evidence that aligns with real-world practice settings will accelerate adoption among hospitals and ambulatory centers. This includes designing trials and registries that reflect diverse patient populations and procedural types while capturing outcomes that matter to both clinicians and payers.

Second, integrating product development with workflow optimization and clinician training enhances the likelihood of successful implementation. Devices and consumables that minimize disruption to established surgical routines, reduce staff burden during dressing changes or device setup, and include clear training pathways will achieve higher uptake. Third, supply chain resilience should be a core strategic pillar; diversifying manufacturing footprints, pursuing regional partnerships, and developing contingency inventory strategies will mitigate tariff and disruption risks. Engaging in collaborative supplier models with key customers can improve predictability and foster shared accountability for clinical outcomes.

Fourth, commercial strategies must increasingly tie to value demonstration. Structuring pilot programs, outcome-based contracts, or bundled offering pilots can create pathways for broader procurement commitments. Finally, leaders should invest in cross-disciplinary stakeholder engagement, ensuring that infection prevention initiatives are co-owned by surgery, nursing, infection control, and supply chain teams to optimize protocol adherence and measure impact comprehensively. Collectively, these actions position organizations to reduce infection risk while maintaining fiscal and operational alignment with evolving healthcare priorities.

Rigorous mixed-methods research approach combining primary clinical insights, secondary literature synthesis, and comparative product mapping to inform strategic conclusions

The research methodology underpinning this analysis combines primary and secondary inquiry to ensure a balanced evidence base. Primary inputs include structured interviews with clinical leaders, procurement professionals, and device innovators, supplemented by advisory consultations that explore real-world implementation challenges and evidence needs. Secondary research encompasses peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications to corroborate product performance claims and identify trends in adoption and standards of care.

Analytical approaches leveraged include comparative product mapping to assess functional differentiation across sutures, wound therapy systems, dressings, and antiseptics, as well as scenario analysis to evaluate potential supply chain and tariff-driven impacts on procurement decisions. Triangulation techniques were applied to reconcile differing stakeholder perspectives and ensure that recommendations reflect both clinical priorities and operational realities. The methodology emphasizes transparency in data sourcing, prioritizes clinical relevance, and seeks to reduce bias by incorporating diverse institutional viewpoints across care settings.

Summarizing the integrated priorities for clinicians and procurement teams to achieve sustainable reductions in surgical site infections and operational risk

In conclusion, effective surgical site infection control requires a multifaceted strategy that integrates product selection, protocol design, and supply chain planning. Clinicians and procurement teams must collaborate to align clinical evidence with operational feasibility, ensuring that chosen interventions deliver both patient-centric benefits and institutional value. Emerging technologies and refined perioperative bundles offer promising avenues to reduce infection risk, but successful adoption depends on robust evidence, workflow compatibility, and resilient sourcing strategies.

As the sector navigates tariff-related shifts, regulatory expectations, and evolving care delivery models, organizations that proactively invest in clinical validation, supplier partnerships, and outcome-based commercial approaches will be best positioned to achieve sustained improvements in surgical quality. The analysis presented here aims to equip decision-makers with the insights needed to prioritize initiatives, evaluate vendor offerings, and implement protocols that collectively advance patient safety and operational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of antimicrobial sutures and barriers to reduce postoperative infection rates
  • 5.2. Integration of UV-C disinfection robots for automated operating room surface sterilization
  • 5.3. Adoption of real-time remote wound monitoring technology for early infection detection
  • 5.4. Shift towards single-use sterile surgical instruments to minimize cross-contamination risks
  • 5.5. Development of bioresorbable antimicrobial dressings enhancing postoperative wound healing
  • 5.6. Regulatory incentives driving hospital investment in advanced infection surveillance systems
  • 5.7. Expansion of telemedicine-led preoperative skin preparation training for remote clinicians

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Surgical Site Infection Control Market, by Product Type

  • 8.1. Antimicrobial Sutures
    • 8.1.1. Silver-Coated Sutures
    • 8.1.2. Triclosan-Coated Sutures
  • 8.2. Negative Pressure Wound Therapy Devices
    • 8.2.1. Single-Use Systems
    • 8.2.2. Traditional Systems
  • 8.3. Surgical Dressings
    • 8.3.1. Alginate Dressings
    • 8.3.2. Foam Dressings
    • 8.3.3. Hydrocolloid Dressings
  • 8.4. Topical Antiseptics
    • 8.4.1. Alcohol-Based
    • 8.4.2. Chlorhexidine-Based
    • 8.4.3. Povidone-Iodine-Based

9. Surgical Site Infection Control Market, by End User

  • 9.1. Ambulatory Surgical Centers
    • 9.1.1. Freestanding Centers
    • 9.1.2. Hospital Affiliated Centers
  • 9.2. Clinics
    • 9.2.1. Outpatient Clinics
    • 9.2.2. Specialty Clinics
  • 9.3. Hospitals
    • 9.3.1. Private Hospitals
    • 9.3.2. Public Hospitals

10. Surgical Site Infection Control Market, by Application

  • 10.1. Intraoperative Wound Irrigation
    • 10.1.1. Antibiotic Irrigation
    • 10.1.2. Saline Irrigation
  • 10.2. Postoperative Wound Management
    • 10.2.1. Dressing Changes
    • 10.2.2. Wound Debridement
  • 10.3. Preoperative Skin Preparation
    • 10.3.1. Chlorhexidine Preparation
    • 10.3.2. Povidone-Iodine Preparation

11. Surgical Site Infection Control Market, by Surgery Type

  • 11.1. Cardiovascular Surgery
    • 11.1.1. Coronary Artery Bypass
    • 11.1.2. Valve Replacement
  • 11.2. General Surgery
    • 11.2.1. Abdominal Procedures
    • 11.2.2. Gastrointestinal Procedures
  • 11.3. Obstetrics And Gynecology Surgery
    • 11.3.1. C Section
    • 11.3.2. Hysterectomy
  • 11.4. Orthopedic Surgery
    • 11.4.1. Joint Replacement
    • 11.4.2. Spinal Surgery

12. Surgical Site Infection Control Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Surgical Site Infection Control Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Surgical Site Infection Control Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 3M Company
    • 15.3.2. Johnson & Johnson
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. Cardinal Health, Inc.
    • 15.3.5. STERIS plc
    • 15.3.6. Ecolab Inc.
    • 15.3.7. B. Braun Melsungen AG
    • 15.3.8. Getinge AB
    • 15.3.9. Molnlycke Health Care AB
    • 15.3.10. Smith & Nephew plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGERY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGERY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. SURGICAL SITE INFECTION CONTROL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. SURGICAL SITE INFECTION CONTROL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SURGICAL SITE INFECTION CONTROL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIMICROBIAL SUTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SILVER-COATED SUTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRICLOSAN-COATED SUTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY NEGATIVE PRESSURE WOUND THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SINGLE-USE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TRADITIONAL SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGICAL DRESSINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALGINATE DRESSINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FOAM DRESSINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HYDROCOLLOID DRESSINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY TOPICAL ANTISEPTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ALCOHOL-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY FREESTANDING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY INTRAOPERATIVE WOUND IRRIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ANTIBIOTIC IRRIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SALINE IRRIGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POSTOPERATIVE WOUND MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY DRESSING CHANGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY WOUND DEBRIDEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY PREOPERATIVE SKIN PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CHLORHEXIDINE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY POVIDONE-IODINE PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGERY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY SURGERY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY CORONARY ARTERY BYPASS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY ABDOMINAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY GASTROINTESTINAL PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SURGICAL SITE INFECTION CONTROL MARKET SIZE, BY OBSTETRICS AND GYNECOLOGY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SURGICAL SITE INFECTION CONTRO